Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel.

Andrea FagioliniJosé Ángel AlcaláThomas AubelWojciech BienkiewiczMats Magnus Knut BogrenJoaquim GagoGiancarlo CerveriMichael CollaFrancisco Collazos SanchezAlessandro CuomoFrieling HelgeEduardo IacoponiPer-Axel KarlssonPradeep PedduMauro PettorrusoHenrique Jorge Ramos PereiraJohan Sahlsten SchölinIngo Bernd Vernaleken

Published in: Annals of general psychiatry (2020)

Based on real-world clinical experience, the panel considered that cariprazine, with its distinct advantages including pharmacokinetics/pharmacodynamics, good efficacy and tolerability, represents a drug of choice in the long-term management of schizophrenia not only for patients with predominant negative symptoms but also for those with positive symptoms.

Keyphrases

bipolar disorder
clinical practice
sleep quality
mental health
open label
emergency department
clinical trial
randomized controlled trial
decision making
drug induced
placebo controlled